Vericel to Report Third-Quarter 2021 Financial Results on November 9, 2021
October 21 2021 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the following webcast and conference call to discuss its
third-quarter 2021 financial results and business highlights.
What: |
Vericel
Corporation Third-Quarter 2021 Earnings Call |
When: |
Tuesday, November 9, 2021 at 8:30am (EDT) |
Where: |
http://investors.vcel.com/events-presentations |
How: |
The conference call will be available live in the Investor
Relations section of the Vericel website at
http://investors.vcel.com/events-presentations. Please access the
site at least 15 minutes prior to the scheduled start time in order
to download the required audio software if necessary. Presentation
slides for the conference call will be available on the webcast and
in the Investor Relations section of the Vericel
website. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation third-quarter 2021
earnings call. If calling from outside the U.S., please use the
international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until November 9, 2022. A replay of the call will also be available
until 11:30am (EDT) on November 13, 2021 by calling (855) 859-2056,
or from outside the U.S. (404) 537-3406. The conference ID is
2998214.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports
medicine and severe burn care markets. The company markets two cell
therapy products in the United States. MACI® (autologous cultured
chondrocytes on porcine collagen membrane) is an autologous
cellularized scaffold product indicated for the repair of
symptomatic, single or multiple full-thickness cartilage defects of
the knee with or without bone involvement in adults. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. The
company also holds an exclusive license for North American
commercial rights to NexoBrid®, a registration-stage biological
orphan product for debridement of severe thermal burns. For more
information, please visit the company’s website at
www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2021 Vericel
Corporation. All rights reserved.
Investor Contacts:Eric Burnsir@vcel.com+1 (734)
418-4411
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024